Atara Biotherapeutics, Inc. ATRA
Nov 3, 2026, 3:49 PM EST
- YTD
- -54.31%
- 1 year
- -40.32%
- Market cap
- 82.96M
- Revenue (ttm)
- 62.39M
- Profit margin
- -290.20%
- EPS (ttm)
- -1.30
- Shares out
- 5.76M
- Forward P/E
- -1.52
- YTD return
- -54.31%
- 1-year return
- -40.32%
- Volume
- 13.77K
- Avg volume
- 41.18K
- Open
- 8.34
- Previous close
- 8.48
- Day's range
- 8.27 – 8.62
- 52-week range
- 3.92 – 19.15
- Beta
- 0.49
- Analysts
- Buy
- Price target
- 16.33 (+97.6%)
2Y -3.28 (-28.20%)
Key statistics
- Enterprise value
- 87.50M
- PEG ratio
- 0.00
- Price / sales
- 1.23
- Price / book
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 2892.70%
- Free cash flow
- -2.97M
- Total cash
- 35.29M
- Total debt
- 52.70M
- Return on equity
- 0.00%
- Short % of float
- 11.36%
- 50-day average
- 10.80
- 200-day average
- 11.70
Analyst view
Consensus: buy
- Target (low)
- 10.00
- Target (mean)
- 16.33
- Target (high)
- 21.00
- Strong buy0
- Buy3
- Hold3
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate -2.34.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 12, 2024 | Sep 1, 2024 | -3.77 | -2.93 | +0.84 | +22.28% |
| Aug 12, 2024 | Jun 1, 2024 | -1.25 | -3.10 | -1.85 | -148.00% |
| May 9, 2024 | Mar 1, 2024 | -9.25 | -5.75 | +3.50 | +37.84% |
| Mar 28, 2024 | Dec 1, 2023 | -15.25 | -14.00 | +1.25 | +8.20% |
| Nov 1, 2023 | Sep 1, 2023 | -15.75 | -16.50 | -0.75 | -4.76% |
| Aug 8, 2023 | Jun 1, 2023 | -16.25 | -17.00 | -0.75 | -4.62% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 20, 2024 | Rodman & Renshaw | init | — | Buy |
| Nov 13, 2024 | Canaccord Genuity | main | Buy | Buy |
| Aug 21, 2024 | HC Wainwright & Co. | reit | — | Neutral |
| Aug 16, 2024 | Mizuho | up | Neutral | Outperform |
| Aug 13, 2024 | Canaccord Genuity | main | Buy | Buy |
| Jul 17, 2024 | Goldman Sachs | main | Sell | Sell |
About Atara Biotherapeutics, Inc.
Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma. Its CAR T immunotherapy pipeline products include ATA3219, currently in Phase 1 trials, as well as ATA3431, under preclinical trials for the treatment of B-cell malignancies and autoimmune diseases; and ATA188 that is in Phase 2 clinical trials to treat multiple sclerosis. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research. Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- atarabio.com
News
Atara Biotherapeutics (NASDAQ:ATRA) Share Price Crosses Above Fifty Day Moving Average – Time to Sell? 
Atara Biotherapeutics' Partner Pierre Fabre Pharmaceuticals Receives FDA Acceptance To Refile Biologics License Application For Tabelecleucel To Treat Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease 
Atara Biotherapeutics Reports that the Resubmitted Tabelecleucel (Tab-cel®) Biologics License Application Has Been Accepted by the U.S. Food and Drug Administration 
Analyzing Atara Biotherapeutics (NASDAQ:ATRA) & Ultragenyx Pharmaceutical (NASDAQ:RARE) 
Atara Biotherapeutics Reports that the Tabelecleucel Biologics License Application Has Been Resubmitted to the U.S. Food and Drug Administration 
Atara Biotherapeutics' Pierre Fabre Pharmaceuticals Partner Refiles Tabelecleucel Biologics License Application With FDA 
Atara Biotherapeutics Reports that the Tabelecleucel Biologics License Application Has Been Resubmitted to the U.S. Food and Drug Administration 
Contrasting Yarrow Bioscience (NASDAQ:YARW) and Atara Biotherapeutics (NASDAQ:ATRA) 
12 Health Care Stocks Moving In Tuesday's Pre-Market Session 
Atara Biotherapeutics Q2 EPS $(0.32), Inline, Sales $630.000K Beat $366.667K Estimate
Your note
Sign in to keep a note on ATRA — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| FUST MATTHEW K. | Director | Stock Award(Grant) | Mar 27, 2024 | 259,000 |
| GALLAGHER CAROL GILTNER | Director | Stock Award(Grant) | Mar 27, 2024 | 629,608 |
| HEIDEN WILLIAM K | Director | Stock Award(Grant) | Mar 27, 2024 | 359,000 |
| HENRICH JILL | Officer | Sale | Nov 17, 2024 | 19,378 |
| HYLLENGREN ERIC J | Chief Operating Officer | Sale | Nov 17, 2024 | 23,392 |
| MALLIK AMEET | Director | Stock Award(Grant) | Mar 27, 2024 | 227,500 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| EcoR1 Capital, LLC | 8.14% | 468,938 | 6.25M | Sep 29, 2024 |
| Redmile Group, LLC | 7.85% | 452,270 | 6.03M | Sep 29, 2024 |
| Citadel Advisors Llc | 4.52% | 260,480 | 3.47M | Sep 29, 2024 |
| Bank of America Corporation | 3.54% | 203,627 | 2.71M | Sep 29, 2024 |
| Vanguard Group Inc | 3.14% | 180,715 | 2.41M | Sep 29, 2024 |
| Millennium Management Llc | 3.06% | 176,053 | 2.35M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.09% | 120,258 | 1.60M | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 0.95% | 54,473 | 726.13K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.44% | 25,277 | 336.94K | Oct 30, 2024 |
| Schwab Strategic Tr-Schwab U.S. Small Cap ETF | 0.43% | 24,599 | 327.90K | Aug 30, 2024 |
| Bridgeway Funds Inc-Ultra Small Company Market Fund | 0.24% | 14,000 | 186.62K | Sep 29, 2024 |
| Variable Insurance Products Fd II-Disciplined Small Cap Portfolio | 0.17% | 9,631 | 128.38K | Sep 29, 2024 |